De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

CareRx Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

CareRx heeft een totaal eigen vermogen van CA$80.3M en een totale schuld van CA$58.8M, wat de schuld-eigenvermogensverhouding op 73.2% brengt. De totale activa en totale passiva bedragen respectievelijk CA$218.6M en CA$138.3M. De EBIT CareRx is CA$7.9M waardoor de rentedekking 0.7 is. Het heeft contanten en kortetermijnbeleggingen van CA$7.2M.

Belangrijke informatie

73.2%

Verhouding schuld/eigen vermogen

CA$58.78m

Schuld

Rente dekkingsratio	0.7x
Contant	CA$7.22m
Aandelen	CA$80.27m
Totaal verplichtingen	CA$138.32m
Totaal activa	CA$218.58m

Recente financiële gezondheidsupdates

Recent updates

CareRx (TSE:CRRX) Seems To Use Debt Quite Sensibly

Oct 03

Analyst Estimates: Here's What Brokers Think Of CareRx Corporation (TSE:CRRX) After Its Second-Quarter Report

Aug 11

Does CareRx (TSE:CRRX) Have A Healthy Balance Sheet?

Apr 22

Market Participants Recognise CareRx Corporation's (TSE:CRRX) Revenues Pushing Shares 28% Higher

Mar 17

CareRx (TSE:CRRX) Takes On Some Risk With Its Use Of Debt

Oct 19

What You Can Learn From CareRx Corporation's (TSE:CRRX) P/S

Aug 22

CareRx (TSE:CRRX) Has A Somewhat Strained Balance Sheet

Sep 22

These 4 Measures Indicate That CareRx (TSE:CRRX) Is Using Debt Extensively

May 14

Here's Why CareRx (TSE:CRRX) Has A Meaningful Debt Burden

Jan 21

Is CareRx Corporation's (TSE:CRRX) Shareholder Ownership Skewed Towards Insiders?

Mar 15

Trade Alert: The Chairman Emeritus Of CareRx Corporation (TSE:CRRX), Jack Shevel, Has Just Spent CA$850k Buying 9.4% More Shares

Feb 08

Reflecting on CareRx's (TSE:CRRX) Share Price Returns Over The Last Three Years

Dec 29

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( CA$60.2M ) van CRRX } dekken niet de korte termijn passiva ( CA$60.7M ).

Langlopende schulden: De kortetermijnactiva van CRRX ( CA$60.2M ) dekken de langetermijnschulden ( CA$77.7M ) niet.

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 64.2% ) CRRX wordt als hoog beschouwd.

Schuld verminderen: CRRX had 5 jaar geleden een negatief eigen vermogen, maar is nu positief en is dus verbeterd.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: Terwijl het verlieslatende CRRX voldoende cash runway heeft voor meer dan 3 jaar, als het zijn huidige positieve vrije kasstroom-niveau behoudt.

Voorspelling contante baan: CRRX is verlieslatend, maar heeft voldoende kasmiddelen voor meer dan 3 jaar, omdat de vrije kasstroom positief is en met 44.5 % per jaar groeit.

CareRx Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

Belangrijke informatie

Recente financiële gezondheidsupdates

CareRx (TSE:CRRX) Seems To Use Debt Quite Sensibly

Does CareRx (TSE:CRRX) Have A Healthy Balance Sheet?

CareRx (TSE:CRRX) Takes On Some Risk With Its Use Of Debt

CareRx (TSE:CRRX) Has A Somewhat Strained Balance Sheet

These 4 Measures Indicate That CareRx (TSE:CRRX) Is Using Debt Extensively

Here's Why CareRx (TSE:CRRX) Has A Meaningful Debt Burden

Recent updates

CareRx (TSE:CRRX) Seems To Use Debt Quite Sensibly

CareRx Corporation Appoints Suzanne Brand as Chief Financial Officer, Effective October 1, 2024

Analyst Estimates: Here's What Brokers Think Of CareRx Corporation (TSE:CRRX) After Its Second-Quarter Report

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

CareRx Corporation to Report Q2, 2024 Results on Aug 08, 2024

New minor risk - Insider selling

CareRx Corporation Announces Board Changes

Consensus EPS estimates increase by 386%

CareRx Corporation Announces CFO Transition

First quarter 2024 earnings: EPS exceeds analyst expectations

Does CareRx (TSE:CRRX) Have A Healthy Balance Sheet?

Market Participants Recognise CareRx Corporation's (TSE:CRRX) Revenues Pushing Shares 28% Higher

CareRx Corporation, Annual General Meeting, May 28, 2024

CareRx Corporation Reports Goodwill and Intangible Assets Impairment Charges for the Fourth Quarter Ended December 31, 2023

Full year 2023 earnings: EPS misses analyst expectations

CareRx Corporation to Report Q4, 2023 Results on Mar 07, 2024

New major risk - Revenue and earnings growth

Third quarter 2023 earnings: EPS exceeds analyst expectations

CareRx Corporation to Report Q3, 2023 Results on Nov 08, 2023

CareRx (TSE:CRRX) Takes On Some Risk With Its Use Of Debt

What You Can Learn From CareRx Corporation's (TSE:CRRX) P/S

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

CareRx Corporation to Report Q2, 2023 Results on Aug 10, 2023

Less than half of directors are independent

Carerx Corporation Announces Director Changes

First quarter 2023 earnings released: CA$0.039 loss per share (vs CA$0.059 loss in 1Q 2022)

Consensus EPS estimates fall by 29%

Forecast breakeven date pushed back to 2025

Price target decreased by 11% to CA$5.23

Full year 2022 earnings released: CA$0.72 loss per share (vs CA$0.65 loss in FY 2021)

CareRx Corporation has completed a Follow-on Equity Offering in the amount of CAD 8.0001 million.

CareRx Corporation announced that it expects to receive CAD 8.0001 million in funding

CareRx Announces Retirement of Dr. Jack Shevel as Director Effective December 31, 2022

No longer forecast to breakeven

Price target decreased to CA$6.09

Less than half of directors are independent

Price target decreased to CA$6.15

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

CareRx Corporation to Report Q3, 2022 Results on Nov 09, 2022

CareRx (TSE:CRRX) Has A Somewhat Strained Balance Sheet

Consensus forecasts updated

Price target decreased to CA$6.93

Carerx Corporation Reports Goodwill and Intangible Assets Impairment Changes for the Three Months Ended June 30, 2022

CareRx Corporation to Report Q2, 2022 Results on Aug 15, 2022

President recently sold CA$230k worth of stock

CareRx Corporation (TSX:CRRX) completed the acquisition of Hogan Pharmacy Partners Ltd.

Consensus EPS estimates fall by 597%

Price target decreased to CA$8.52

These 4 Measures Indicate That CareRx (TSE:CRRX) Is Using Debt Extensively

Forecast breakeven date pushed back to 2024

CareRx Corporation to Report Q1, 2022 Results on May 11, 2022

Consensus forecasts updated

Less than half of directors are independent

CareRx Corporation Announces Executive Changes

CareRx Corporation, Annual General Meeting, Jun 07, 2022

CareRx Corporation (TSX:CRRX) entered into a definitive asset purchase agreement to acquire Hogan Pharmacy Partners Ltd for $4.4 million.

CareRx Corporation (TSX:CRRX) entered into a definitive asset purchase agreement to acquire Hogan Pharmacy Partners Ltd for $4.4 million.

Consensus forecasts updated

No longer forecast to breakeven

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Carerx Corporation Expands the Scope and Product Offering of Its Medical Supplies Business Under A New Brand, Revicare

Here's Why CareRx (TSE:CRRX) Has A Meaningful Debt Burden

Third quarter 2021 earnings released: CA$0.11 loss per share (vs CA$0.28 loss in 3Q 2020)

CareRx Corporation (TSX:CRRX) completed the acquisition of Long-Term Care Pharmacy Division of Medical Pharmacies Group Limited for CAD 72.9 million.

Consensus EPS estimates fall to -CA$0.72

Second quarter 2021 earnings released: CA$0.28 loss per share (vs CA$0.75 loss in 2Q 2020)

CareRx Corporation (TSX:CRRX) completed the acquisition of pharmacy fulfillment centre and portion of long-term care pharmacy services business of Rexall Pharma Plus Ltd.

Director Lyle Oberg has left the company